Match!
Aaron M. Goodman
University of California, San Diego
43Publications
9H-index
761Citations
Publications 43
Newest
#1Daniella Klebaner (UCSD: University of California, San Diego)
#2Divya Koura (UCSD: University of California, San Diego)H-Index: 3
Last.Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 9
view all 6 authors...
Abstract Hepatosplenic T-cell Lymphoma (HSTCL) is a rare peripheral T-cell lymphoma that disproportionately affects individuals with a clinical history of immunosuppression. It carries a poor prognosis, and due to its rarity, there is no single or well-established treatment. We conducted the largest-to-date individual-level meta-analysis based on literature searches to determine the best induction therapy for HSTCL. We compared response rates and survival among patients who received “non-CHOP-ba...
#1Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 9
#2Ethan Sokol (Foundation Medicine)H-Index: 3
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 5 authors...
Programmed death receptor-1/ligand 1 (PD-1/L1) antibodies can induce durable remissions in malignancies. However, response rates are only approximately 10% to 20% in unselected patients versus approximately 50% in microsatellite instability–high (MSI-high) tumors, probably related to high tumor mutational burden (TMB). Pembrolizumab is approved for MSI-high or deficient mismatch repair tumors. However, outside of colorectal and endometrial carcinoma, only a small subset of tumors were MSI-high, ...
#1Filip Janku (University of Texas MD Anderson Cancer Center)H-Index: 41
#2Eli L. Diamond (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 19
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 10 authors...
The BRAFV600E mutation and BRAF inhibitor responsiveness characterize ~50% of patients with the non-Langerhans cell histiocytosis (non-LCH) Erdheim-Chester disease (ECD). We interrogated the non-LCH molecular landscape (ECD, n=35; Rosai-Dorfman disease [RDD], n=3; mixed ECD/RDD, n=1) using BRAFV600E polymerase chain reaction and/or next-generation sequencing (tissue and cell-free DNA [cfDNA] of plasma and/or urine). Of 34 evaluable patients, 17 (50%) had the BRAFV600E mutation. Of 31 patients ev...
#1Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 9
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 10 authors...
Advanced and metastatic squamous cell carcinomas (SCC) are common and difficult-to-treat malignancies. We assessed 75 immunotherapy-treated patients with SCC from a clinically annotated database of 2,651 patients, as well as 9,407 patients from a deidentified database for molecular features that might influence checkpoint blockade response. SCCs had higher tumor mutational burdens (TMB) than non-SCCs (P
#1Stephanie H. Kim (UCSD: University of California, San Diego)H-Index: 8
#2Jennifer Namba (UM: University of Montana)
Last.Ila M. Saunders (UM: University of Montana)H-Index: 3
view all 5 authors...
PurposeLow-molecular-weight heparins are currently the recommended antithrombotic therapy for treatment and prevention of malignancy-related venous thromboembolism. Currently, the evidence evaluati...
#1Celina AngH-Index: 3
#2Samuel J. KlempnerH-Index: 19
Last.Sherri Z. MillisH-Index: 11
view all 11 authors...
// Celina Ang 1 , Samuel J. Klempner 2 , Siraj M. Ali 3 , Russell Madison 3 , Jeffrey S. Ross 3 , Eric A. Severson 3 , David Fabrizio 3 , Aaron Goodman 4 , Razelle Kurzrock 4 , James Suh 3 and Sherri Z. Millis 3 1 Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA 2 Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA 3 Foundation Medicine, Cambridge, MA, USA 4 Department o...
#1Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 9
#2Philip CohenH-Index: 48
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 5 authors...
#1Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 9
#2Rachel Marty Pyke (UCSD: University of California, San Diego)H-Index: 2
Last.Razelle KurzrockH-Index: 99
view all 9 authors...
149Background: MHC-1 molecules present intracellular peptides on the surface of tumor cells for recognition by CD8+ cytotoxic T-cells. Cancers with a high tumor mutational burden (TMB) are more lik...
#1Kimberly M Lau (UCSD: University of California, San Diego)
#2Ila M. Saunders (UM: University of Montana)H-Index: 3
Last.Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 9
view all 3 authors...
Pegaspargase, a long acting formulation of L-asparaginase, is an asparagine specific enzyme that selectively kills leukemic cells by depleting plasma asparagine. Pegaspargase is FDA approved for the first-line treatment of adult acute lymphoblastic leukemia and is a critical component of numerous multi-chemotherapeutic regimens. Pegaspargase is associated with well-described toxicities including hypersensitivity reactions, hepatotoxicity, and thrombosis. However, hypertriglyceridemia is a much r...
12345